BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9523662)

  • 1. Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
    Cohen RJ; Chan WC; Edgar SG; Robinson E; Dodd N; Hoscek S; Mundy IP
    Br J Urol; 1998 Mar; 81(3):413-8. PubMed ID: 9523662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores.
    Grossklaus DJ; Coffey CS; Shappell SB; Jack GS; Cookson MS
    BJU Int; 2001 Nov; 88(7):722-6. PubMed ID: 11890243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
    Kimura K; Tsuzuki T; Kato M; Saito AM; Sassa N; Ishida R; Hirabayashi H; Yoshino Y; Hattori R; Gotoh M
    Prostate; 2014 May; 74(6):680-7. PubMed ID: 24481730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ability of sextant biopsies to predict radical prostatectomy stage.
    Wills ML; Sauvageot J; Partin AW; Gurganus R; Epstein JI
    Urology; 1998 May; 51(5):759-64. PubMed ID: 9610589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors.
    Grober ED; Tsihlias J; Jewett MA; Sweet JM; Evans AJ; Trachtenberg J; Robinette M; Nam RK
    Can J Urol; 2004 Feb; 11(1):2157-62. PubMed ID: 15003158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
    Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
    J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
    Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
    Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
    Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
    Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.